Home | AI powered stock trade ideas | Market Signals | Breaking Out | New Green AI Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

AI Powered Stock Trade Ideas
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart


All Chart Prices as of Previous Day Close

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Last Price: 42.55 - Change: 0.54 - Change %: 1.2854
02/23/2024 16:10:00 EST

Baxter International Inc (BAX)

Industry: Medical Instruments & Supplies

Price Support Resistance

In the past 20 trading days, BAX has been trading in a range between $41.77 and $38.53 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

BAX is trading below resistance at $49.29, about 16% to the upside. There is support at $41.41 -3% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.

Upside / Downside Potential

Baxter International Inc (BAX) entered a Green zone 21 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $47.08, a potential upside of 10.65% from the recent price of 42.55. Our AI powered stock target predictor currently has a target price of $29.42 a potential move of -31%. The stock is trading 16.26% (potential upside) below its 52 week high of $49.47 and 38.33 % (potential downside) above its 52 week low of $30.76 - based on the recent price.

Company Summary

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care.

BAX Website


Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation
Baxter to act as exclusive partner to Spectral for 10 years following PMX approval by U.S. FDA Baxter to act as exclusive partner to Spectral for 10 years following PMX approval by U.S. FDA
Source: GlobeNewsWire
Wed, 21 Feb 2024 16:00:00 -0500
Sentiment: Neutral
Baxter: Market-Leading Medical Supplier With Lots In The Pipeline
Baxter International gets its buy rating from December reaffirmed, agreeing with today's bullish consensus from SA analysts and Wall Street. Positive drivers of the bull call include recent Q4 performance, declining debt, innovative new products in the pipeline, and dividend growth. Some weak spots are an unremarkable dividend yield or future revenue growth vs peers, as well as the nature of lengthy FDA approvals on products.
Source: Seeking Alpha
Wed, 21 Feb 2024 04:34:18 -0500
Sentiment: Positive
Baxter To Spin-Off Vantive (Kidney Care Unit) In July 2024
On February 8, 2024, Baxter International BAX Inc. (NYSE: BAX, $39.64, Market Capitalization: $20.1 billion), a global medtech leader, reported steady 4Q23 results, with a mild beat vs consensus on revenues and adjusted EPS. In 4Q23, consolidated revenue increased by 3.7% YoY to $3.9 billion (up 3% on a constant currency basis).
Source: Forbes
Thu, 15 Feb 2024 13:53:45 -0500
Sentiment: Neutral
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.
Source: GlobeNewsWire
Thu, 15 Feb 2024 07:41:00 -0500
Sentiment: Neutral
Baxter Declares Quarterly Dividend
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on April 1, 2024, to stockholders of record as of March 1, 2024. The indicated annual dividend rate is $1.16 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of dia.
Source: Business Wire
Mon, 12 Feb 2024 18:15:00 -0500
Sentiment: Neutral
Instituions Institution %: 92.541
Last QTR Institution change: 41226464

Insiders %: 0.262
Insiders Purchases last QTR: 0
Insiders Sales last QTR: 3930
Insiders Net last QTR: -3930

Analyst Ratings
Target Price: 47.08
Overall Rating: 3.6
Strong Buys (5): 4
Buys (4): 1
Holds (3): 10
Sells (2): 0
Strong Sells (1): 0

52 Week Hi: 49.4658
52 Week Low: 30.7629
Beta: 0.614
50 Day MA: 39.331
200 Day MA: 39.8661

Earnings / Revenue Trends
Qtr Earnings Growth YOY: 0.338
Qtr Revenue Growth YOY: 0.037
Forward PE: 14.771
Trailing PE: 0

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!


Stock Analyzed Each Night


Easily Upload Track Your Stocks


See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.